Institutional review boards (IRBs) are charged with protecting the rights and welfare of people who participate in research. According to the reporting, many medical ethicists now contend that the U.S. IRB system has drifted from that central mission and become overly influenced by the priorities of companies sponsoring research. That shift, they say, undermines the primary ethical obligation to research participants and damages public trust in science.
The source frames the debate as rooted in decades of experience among research ethicists who view current incentives and structures as misaligned with participant protection. It emphasizes that persistent ethical concerns are not merely theoretical but have been highlighted by concrete scandals and investigations.
Stephen Rosenfeld and Patricia Seymour founded the not-for-profit North Star Review Board after becoming disillusioned with the prevailing oversight system. The reporting describes them as research ethicists who, over many years, concluded that IRBs had “lost their way.” Their effort to create a nonprofit review board was presented as an attempt to re-center oversight on the welfare of human participants and to rebuild trust in scientific research.
The article highlights the founders’ motivation as ethical and trust-focused. However, the source did not provide operational specifics about North Star’s governance, funding model, review procedures, or early results demonstrating improved protections.
The article recounts a notable historical example that critics use to illustrate systemic problems: a 2009 sting by the Government Accountability Office. In that test, the GAO submitted a deliberately bogus, unethical protocol to a small sample of for-profit IRBs to see whether they would detect and reject it. One of the companies tested, Coast IRB in Colorado, approved the fictitious application despite features that, by FDA guidance, matched several examples of “significant risk.”
The GAO’s exercise was cited in the reporting as evidence that some for-profit IRBs were vulnerable to unethical manipulation. After the sting, Coast IRB was shut down. The episode is presented as emblematic of why reformers argue for structural change in how review boards operate and are financed.
Although the Coast IRB case led to that entity’s closure, the article reports that major, systemwide reform did not follow. Experts interviewed told STAT that the underlying structural problem persisted despite the high-profile scandal. The reporting suggests that isolated enforcement or shutdowns have not been sufficient to alter incentives or the broader ecosystem that critics say allows conflicts of interest to influence IRB decisions.
The piece notes the gap between the occurrence of scandals and comprehensive reform, but it does not catalog specific policy proposals that were advanced or rejected after the GAO findings, nor does it list regulatory actions beyond the Coast IRB shutdown.
North Star’s founders offer a nonprofit alternative intended to minimize commercial influence on review processes. The article positions the nonprofit model as a response to conflicts of interest critics associate with for-profit IRBs and as a means to prioritize participant safety and ethical review.
Reporting emphasizes the normative rationale: that removing or reducing profit motives in oversight could better align IRB incentives with participant protection and public trust. The source presents this approach as an intervention aimed at addressing long-standing ethical concerns about the current system.
However, the article did not provide empirical evidence from North Star showing that nonprofit review produces objectively stronger protections, nor did it compare outcomes across nonprofit, academic, and commercial IRBs in a systematic way.
The STAT article communicates the ethical case for a nonprofit IRB model and recounts historical failures that motivate reform. At the same time, several important operational and evidentiary details were not reported in the source. These include specifics on North Star’s funding streams, governance structure, staffing and expertise, procedural differences from existing IRBs, measures of review quality, numbers of protocols reviewed, or any regulatory interactions beyond the founders’ stated motivations.
The reporting also does not document whether regulators, institutional sponsors, or research communities have endorsed or formally adopted North Star’s model, nor does it describe any measurable impact on participant safety or trial integrity.
Taken together, the source presents a critique of current IRB incentives, a nonprofit alternative championed by experienced ethicists, and a historical example—the 2009 Government Accountability Office sting and Coast IRB—that illustrates system vulnerabilities. Where the article is explicit, it highlights ethical concerns and the potential of nonprofit oversight; where it is silent, it leaves operational details, empirical evidence, and regulatory responses unreported.